2型糖尿病诊断年龄与后续癌症发病率之间的关联:一项纵向人群队列研究
该前瞻性人群队列纳入2011至2018年新诊断的428,568例2型糖尿病患者,按诊断年龄分为20-54岁至≥75岁共六组,与上海一般人群比较总体及14部位癌症发病率。结果显示,诊断年龄越轻,总体及部位特异性癌症发病率越高;总体癌症年龄标化发病率为501/10万人年,标准化发病比为1.10。
要点
- 2型糖尿病诊断年龄越轻,总体癌症及多种部位特异性癌症的年龄标化风险越高。
- 20-54岁诊断组总体癌症标准化发病比为1.48,≥75岁诊断组为0.86。
- 作者认为,上述结果提示需按诊断年龄对2型糖尿病进行分层管理。
核心结论
- 新诊断2型糖尿病患者中,诊断年龄越轻,总体癌症及部位特异性癌症的年龄标化风险越高。
- 作者认为,上述发现提示需要按2型糖尿病诊断年龄进行分层管理。
- 与多种血管结局类似,早发2型糖尿病的年龄标化癌症风险高于晚发2型糖尿病。
研究设计与样本
- 前瞻性人群纵向队列研究,纳入2011至2018年新诊断的428,568例2型糖尿病患者。
- 按诊断年龄分为20-54、55-59、60-64、65-69、70-74和≥75岁共六组。
- 与一般人群比较总体及14部位特异性癌症发病率;一般人群比较基于100,649,346人年。
主要发现
- 2型糖尿病队列记录总体癌症18,853例,一般人群记录582,643例。
- 2型糖尿病患者总体癌症年龄标化发病率为501(95%CI:491,511)/10万人年,标准化发病比(SIR)为1.10(1.09,1.12)。
- 诊断年龄20-54、55-59、60-64、65-69、70-74和≥75岁组的总体癌症SIR分别为1.48(1.41,1.54)、1.30(1.25,1.35)、1.19(1.15,1.23)、1.16(1.12,1.20)、1.06(1.02,1.10)和0.86(0.84,0.89)。
- 男性和女性中均观察到部位特异性癌症的类似趋势,包括呼吸系统、结直肠、胃、肝、胰腺、膀胱、中枢神经系统、肾和胆囊癌症以及淋巴瘤。
关键数值与推荐
- 总体癌症比较采用年龄标化发病率和标准化发病比(SIR)。
- 按诊断年龄分六组:20-54、55-59、60-64、65-69、70-74和≥75岁。
临床怎么用
- 作者认为,上述发现提示需要按2型糖尿病诊断年龄进行分层管理。
- 原文未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Diabetes presenting at a younger age has a more aggressive nature. We aimed to explore the association of age at type 2 diabetes mellitus (T2DM) diagnosis with subsequent cancer incidence in a large Chinese population. RESEARCH DESIGN AND METHODS: The prospective population-based longitudinal cohort included 428,568 newly diagnosed T2DM patients from 2011 to 2018. Participants were divided into six groups according to their age at diagnosis: 20-54, 55-59, 60-64, 65-69, 70-74, and ≥75 years. The incidence of overall and 14 site-specific cancers was compared with the Shanghai general population including 100,649,346 person-years. RESULTS: A total of 18,853 and 582,643 overall cancer cases were recorded in the T2DM cohort and the general population. The age-standardized rate of overall cancer in T2DM patients was 501 (95% CI: 491, 511) per 100,000 person-years, and the standardized incidence ratio (SIR) was 1.10 (1.09, 1.12). Younger age at T2DM diagnosis was associated with higher incidence of overall and site-specific cancers. SIRs for overall cancer with T2DM diagnosis at ages 20-54, 55-59, 60-64, 65-69, 70-74, and ≥75 years were 1.48 (1.41, 1.54), 1.30 (1.25, 1.35), 1.19 (1.15, 1.23), 1.16 (1.12, 1.20), 1.06 (1.02, 1.10), and 0.86 (0.84, 0.89), respectively. Similar trends were observed for site-specific cancers, including respiratory, colorectum, stomach, liver, pancreatic, bladder, central nervous system, kidney, and gallbladder cancer and lymphoma among both males and females. CONCLUSIONS: Our findings highlight the necessity of stratifying management for T2DM according to age of diagnosis. As with a range of vascular outcomes, age-standardized cancer risks are greater in earlier compared with later onset T2DM.
引用
- Li Y, Tian J, Hou T, et al. Association Between Age at Diabetes Diagnosis and Subsequent Incidence of Cancer: A Longitudinal Population-Based Cohort. Diabetes Care. 2024. PMID: 38237119. doi:10.2337/dc23-0386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。